<?xml version='1.0' encoding='utf-8'?>
<document id="15566301"><sentence text="Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position."><entity charOffset="0-26" id="DDI-PubMed.15566301.s1.e0" text="Tetrasubstituted imidazole" /></sentence><sentence text="We prepared novel 1,2,4,5-tetrasubstituted imidazole derivatives with high anti-inflammatory activity by using our previously described regiospecific synthesis"><entity charOffset="18-52" id="DDI-PubMed.15566301.s2.e0" text="1,2,4,5-tetrasubstituted imidazole" /></sentence><sentence text=" Systematic optimization of the imidazole N-1 substituent resulted in compound 9b that potently inhibited the mitogen-activated protein kinase p38 (p38 IC(50) = 0"><entity charOffset="32-41" id="DDI-PubMed.15566301.s3.e0" text="imidazole" /></sentence><sentence text="218 microM) as well as the release of the proinflammatory cytokines interleukin-1 beta (IL-1 beta) and tumor necrosis factor alpha (TNF alpha) from human whole blood after stimulation with LPS" /><sentence text=" Furthermore, compound 9b exhibited reduced cytochrome P450 interaction in comparison with SB203580" /><sentence text=" This result is particularly important, since cytochrome P450 interaction is observed for some p38 inhibitors and in turn can potentially cause drug-drug interaction or lead to other hepatic changes such as P450 enzyme induction" /><sentence text="" /></document>